Pictilisib (GDC-0941) is an orally accessible pan class I PI3K inhibitor currently being investigated in clinical researches for the treatment of progressive breast cancer.42, 43Pictilisib nonspecifically inhibits all four isoforms of PI3K because it binds to the ATP (adenosine triphosphate)-binding pocket. Here, PIK3CA is linked to breast carcinoma.